Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
26.40
+0.18 (0.69%)
Nov 21, 2024, 4:00 PM EST - Market closed
Royalty Pharma Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Royalty Pharma stock have an average target of 41.67, with a low estimate of 28 and a high estimate of 51. The average target predicts an increase of 57.84% from the current stock price of 26.40.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Royalty Pharma stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $60 → $40 | Strong Buy | Maintains | $60 → $40 | +51.52% | Oct 25, 2024 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $50 → $51 | Strong Buy | Maintains | $50 → $51 | +93.18% | Aug 14, 2024 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $48 → $51 | Buy | Maintains | $48 → $51 | +93.18% | Jul 11, 2024 |
| UBS | UBS | Strong Buy → Hold Downgrades $28 | Strong Buy → Hold | Downgrades | $28 | +6.06% | Jun 3, 2024 |
| B of A Securities | B of A Securities | Strong Buy Maintains $40 → $38 | Strong Buy | Maintains | $40 → $38 | +43.94% | Apr 12, 2024 |
Financial Forecast
Revenue This Year
2.65B
from 2.35B
Increased by 12.38%
Revenue Next Year
2.94B
from 2.65B
Increased by 11.26%
EPS This Year
4.01
from 2.53
Increased by 58.32%
EPS Next Year
4.45
from 4.01
Increased by 10.88%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 2.9B | 3.6B | 3.9B | ||
| Avg | 2.6B | 2.9B | 3.2B | ||
| Low | 2.2B | 2.4B | 2.5B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 23.3% | 36.8% | 32.7% | ||
| Avg | 12.4% | 11.3% | 9.7% | ||
| Low | -7.8% | -8.8% | -15.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 4.41 | 5.18 | 5.91 | ||
| Avg | 4.01 | 4.45 | 4.93 | ||
| Low | 3.43 | 3.95 | 4.14 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 74.1% | 29.0% | 32.9% | ||
| Avg | 58.3% | 10.9% | 10.7% | ||
| Low | 35.4% | -1.5% | -7.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.